Highlighting the latest ophthalmology-related news reported across MJH Life Sciences™.
Highlighting the latest ophthalmology-related news reported across MJH Life Sciences™.
FDA Approves First Nasal Spray for Treatment of Dry Eye Disease
This week, the FDA approved the first nasal spray indicated for the treatment of dry eye disease (DED) in the United States, according to Ophthalmology Times®.
Varenicline solution nasal spray 0.03 mg, sold as Tyrvaya and developed by Oyster Point Pharma, is a highly selective cholingergic agonist designed to activate the trigeminal parasympathetic pathway. Notably, its novel nasal delivery was indicated to potentially improve self-administration of DED therapy for patients who have difficulty administering topical eye drops independently.
Based on evidence of the ONSET-1, ONSET-2, and MYSTIC clinical trials, the nasal spray was associated with statistically significant improvements in tear film production and further improvements from baseline in eye dryness. The most common adverse events were sneezing, cough, throat irritation, and nose irritation.
Innovations in Ophthalmologic Surgery Care for Pediatric Populations
In an article by Ophthalmology Times®, 4 key innovations in the surgical care of pediatric ophthalmology patients were noted at the Women in Ophthalmology 2021 Summer Symposium:
In pediatric patients with refractory glaucoma, the use of ECP vs transscleral ciliary ablation was indicated to provide a minimally invasive and safer technique. Notably, less than 1% of eyes experiencing phthisis in the absence of retinal detachment were reportedly treated with ECP compared with over 30% in eyes treated transsclerally.
Furthermore, evaluating pediatric patients with cataract via UBM was said to better enable surgery planning and avoid intraoperative surprises. Speaking on a particular case study of a 1-month child with bilateral cataract who had to have their surgery postponed for 3 months due to required treatment for comorbid heart failure, UBM imaging conducted prior to the scheduled surgery uncovered a significant decrease in crystalline lens thickness that helped guide appropriate surgical techniques.
Assessing Treatment Options for Presbyopia
Despite risk of age-related blurry near vision, known as presbyopia, increasing naturally among a growing older adult population, there are no approved drug therapies, with all available interventions, such as contacts, lens exchange, and monovision, reportedly having issues.
As reported by Ophthalmology Times®, demand for interventions, especially those beyond corrective reading glasses, has been noted, with over two-thirds of patients indicating their preference for eye drops. Development of eye drops for the treatment of presbyopia has generated several investigational therapies, in which the closest to achieving commercial availability is Allergan’s AGN-190584.
AGN-190584 was shown in the GEMINI I trial to meet its primary and key secondary end points without compromising distance vision. The drop achieved a 3-line or greater improvement in the mesopic distance corrected near vision, with onset in 15 minutes.
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Prices for care at hospital trauma centers vary across hospitals; drug shortages reached a record high during the first quarter of 2024; although 3 of the biggest makers of asthma inhalers pledged to cap out-of-pocket costs for some US patients at $35, these do not apply to daily inhalers used by the youngest kids with asthma.
Read More
Commonwealth Fund Report Details Pervasive Racial and Ethnic Disparities in US Health Care, Outcomes
April 18th 2024Using 25 health system performance indicators, the Commonwealth Fund 2024 State Health Disparities Report evaluated racial and ethnic disparities in health care and health outcomes both within and across US states and highlighted the urgent need for equitable health care policies and practices in the US.
Read More